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INTRODUCTION
Diabetic nephropathy is generally considered a non-
immune renal disorder; however, the infiltration of in-
flammatory cells within glomeruli and tubulointersti-
tium can be commonly observed in both human diabetic
patients and animal models of diabetes1-3). Monocytes/
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Purpose: A previous study has demonstrated that colchicine abrogated intercellular adhesion molecule
(ICAM)-1 and fibronectin expression in renal cells exposed to high glucose media, but the underlying
mechanism was not clarified. This study was undertaken to elucidate whether it was attributed to the
inhibitory effect of colchicine on locally-produced angiotensin II (AII) under diabetic conditions
Methods: Rat mesangial cells and NRK-52E cells were cultured in media containing 5.6 mM glucose
(NG), NG+10-7 M AII (NG+AII), or 30 mM glucose (HG) with or without 10-8 M colchicine (Col) and/or
10-6 M L-158,809, an AII type 1 receptor blocker (ARB). ICAM-1 and fibronectin mRNA and protein
expressions were determined by real-time PCR (RT-PCR) and Western blot, respectively. AII levels in
conditioned media were determined by ELISA.
Results: AII levels in conditioned media were significantly higher in HG-stimulated mesangial cells and
NRK-52E cells compared to NG cells (p<0.05). ICAM-1 and fibronectin mRNA and protein expression
were significantly increased in renal cells exposed to HG media (p<0.05 or p<0.01), and these increases
were significantly ameliorated by colchicine or ARB treatment (p<0.05). Colchicine and ARB also signi-
ficantly attenuated AII-induced ICAM-1 and fibronectin expression (p<0.05). However, there was no
additive inhibitory effect of colchicine and ARB on the increases in ICAM-1 and fibronectin expression.
Conclusion: Colchicine abrogated increased ICAM-1 and fibronectin expression in renal cells under
diabetic conditions, which is partly mediated by inhibiting HG-induced locally-produced AII. These fin-
dings provide a new renoprotective mechanism of colchicine in diabetic nephropathy in addition to its
impact on leukocyte functions.
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macrophages are the principle inflammatory cells found
in the diabetic kidney and accumulating evidence has
suggested that monocytes/macrophages play a critical
role in the development and progression of glomerular
and tubulointerstitial lesions in diabetic nephropathy.
Even though strict blood glucose control and tight blood
pressure control and the use of renin-angiotensin
system (RAS) blockers have been the gold standard
for the management of diabetic patients, the admini-
stration of anti-inflammatory agents has been recently
shown to reduce inflammatory cell infiltration and to
prevent renal injury in experimental diabetic animals
4-6). Irradiation also had a beneficial effect on diabetic
nephropathy via an anti-inflammatory mechanism7).
These findings suggest that an inflammatory process
may also contribute to the pathogenesis of diabetic
nephropathy and that drugs possessing anti-inflam-
matory action can be used for preventing nephropathy
in diabetic patients.
Colchicine is an old drug commonly used to relieve‘ ’
pain in acute gout and is known to inhibit the function
and motility of granulocytes and other motile cells8).
In addition, colchicine was demonstrated to prevent
experimental pulmonary and hepatic fibrosis9-12).
Moreover, recent studies showed that colchicine pre-
vented renal injury in an animal model of chronic cyc-
losporine nephrotoxicity and in experimental diabetic
rats via its anti-inflammatory action6, 13). Furthermore,
we previously found that colchicine abrogated inter-
cellular adhesion molecule (ICAM)-1 and fibronectin
expression in renal cells exposed to high glucose
medium6). However, the underlying mechanism how
colchicine ameliorates increased ICAM-1 and fibro-
nectin expression under diabetic conditions was not
clarified. Since a previous study suggested that col-
chicine may indirectly inhibit the action of AII14, 15),
we surmised that colchicine may inhibit locally-pro-
duced angiotensin II under diabetic conditions, resulting
in reduced ICAM-1 and fibronectin expression. In
this study, we investigated the effect of colchicine on
the expression of ICAM-1 and fibronectin in high glu-
cose- and angiotensin II (AII)-stimulated mesangial
cells and tubular epithelial cells. In addition, the effects of
colchicine on high glucose-induced ICAM-1 and fi-
bronectin expression were compared to those of L-
158,809, an AII type 1 receptor (AT1R) blocker (ARB).
MATERIALS AND METHODS
1. Cell culture
Primary culture of rat mesangial cells were done as
previously described16). Identification of mesangial
cells was performed by their characteristic stellate
appearance in culture and confirmed by immunofluo-
rescent microscopy for the presence of actin, myosin,
and Thy-1 antigen and the absence of factor VIII and
cytokeratin (Synbiotics, San Diego, CA, USA). Me-
sangial cells and NRK-52E cells, immortalized rat
tubular epithelial cells, were maintained in RPMI 1640
and DMEM medium, respectively, supplemented with
5% fetal bovine serum (FBS), 100 U/mL penicillin,
100 mg/mL streptomycin, and 26 mM NaHCO3, and
were grown at 37 in humidified 5% CO℃ 2 in air. Sub-
confluent mesangial cells and NRK-52E cells were
serum restricted for 24 hours, after which the medium
was replaced by serum-free medium containing 5.6
mM glucose (NG), NG+24.4 mM mannitol (NG+M),
NG+10-7 M AII (NG+AII), or 30 mM glucose (HG)
with or without 10-8 M colchicine (Col) and/or 10
-6
M L-158,809, an ARB. At 24 hours after the media
change, cells were harvested and the conditioned
culture media were collected.
2. Measurement of AII by ELISA
AII levels were determined in conditioned culture
media using a commercial ELISA kit (Peninsula Labo-
ratories, Belmont, CA, USA) by the avidin-streptavidin
method, as previously described17). Briefly, samples
or standards were incubated with anti-AII antibody
and biotinylated AII (B-AII) in 96-well plates coated
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with Staphylococcus aureus Protein A. After incuba-
tion, the unbound B-AII was removed by washing,
and the bound B-AII was determined by reaction of
streptavidin-HRP in the wells using TMB (3,3 ,5,5 -’ ’
tetramethylbenzidine dihydrochloride) and H2O2 as a
substrate. The reaction was terminated with 2 N HCl,
and the color intensity in each well was read at 450
nm using an ELISA microtiter plate reader. The AII
amount in each well was calculated from the standard
curve and normalized with the total protein content,
which had been previously determined by a modified
Lowry method.
3. 125I-AII binding
The AII binding assays were performed as described
by Becker and Harris18). Briefly, after the incubation
of cells with 30 mM glucose for 24 hours, confluent
monolayers of cells were washed twice with ice-cold
phosphate-buffered saline (PBS) containing 0.1% al-
bumin (PBS-A), further incubated in PBS-A sup-
plemented with 125I-[Sar1, Ile8] AII (10-10M) at 4℃
for 4 hours, followed by three washes with the same
ice-cold PBS-A. After solubilization in 0.5 N NaOH
(1 mL), 900 L of each sample were transferred intoμ
a scintillation tube and counted in a counter. Specificγ
binding was determined by the equation (total binding
- binding in the presence of 1 M unlabeled AII). Theμ
radioactive counts in each sample normalized with the
total protein content, which was previously determined
by a modified Lowry method.
4. Total RNA extraction
Total RNA from renal cortical tissue was extracted
as previously described16). Briefly, 100 L of RNAμ
STAT-60 reagent (Tel-Test, Inc., Friendswood, TX,
USA) was added to the renal cortical tissues lysed by
the procedure of freezing and thawing repeated three
times. Another 700 L of RNA STAT-60 reagent wasμ
then added and the mixture was vortexed and stored
for 5 minutes at room temperature. Next, 160 L ofμ
chloroform was added and the mixture was shaken
vigorously for 30 seconds. After 3 minutes, the mix-
ture was centrifuged at 12,000 g for 15 minutes at×
4 and the upper aqueous phase containing the ex℃ -
tracted RNA was transferred to a new tube. RNA was
precipitated from the aqueous phase by adding 400 Lμ
of isopropanol and then pelleted by centrifugation at
12,000 g for 30 minutes at 4 . The RNA precipitate× ℃
was washed with 70% ice-cold ethanol, dried using
a Speed Vac, and dissolved in DEPC-treated distilled
water. RNA yield and quality were assessed based
on spectrophotometric measurements at wavelengths
of 260 and 280 nm. Total RNA from mesangial cells
and NRK-52E cells was extracted in a similar way.
5. Reverse transcription
First strand cDNA was made by using a Boehringer
Mannheim cDNA synthesis kit (Boehringer Mannheim
GmbH, Mannheim, Germany). Two g of total RNAμ
extracted from renal cortex and cultured cells were
reverse transcribed using 10 M random hexanucleoμ -
tide primer, 1 mM dNTP, 8 mM MgCl2, 30 mM KCl,
50 mM Tris-HCl, pH 8.5, 0.2 mM dithiothreithol, 25
U RNAse inhibitor, and 40 U AMV reverse transcrip-
tase. The mixture was incubated at 30 for 10 minutes℃
and 42 for 1 hour followed by inactivation of the℃
enzyme at 99 for 5 minutes.℃
6. Real-time polymerase chain reaction (Real-time
PCR)
The primers used for MCP-1, ICAM-1, fibronectin,
and 18s amplification were as follows: ICAM-1 sense
5 -AGGTA TCCATCCATCCCAC-3 , antisense 5 -’ ’ ’
GCCGAGGTTCTCGTCTTC-3 ; fibronectin sense 5 -’ ’
TGACAACTGCCGTAGACCTGG-3 , antisense 5-TAC’ ’
TGGTTGTAGGTGTGGCCG-3 ; and 18s sense 5 -’ ’
AGTCCCTGCCCTTTGT ACACA-3 , antisense 5 -’ ’
GATCCGAGGGCCTCACTAAAC-3 . cDNAs from 25’
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ng RNA of renal cortical tissue or cultured cells per
reaction tube were used for amplification.
Using the ABI PRISMⓇ 7700 Sequence Detection
System (Applied Biosystems, Foster City, CA, USA),
PCR was performed with a total volume of 20 L inμ
each well, containing 10 L of SYBR Greenμ Ⓡ PCR
Master Mix (Applied Biosystems), 5 L of cDNA, andμ
5 pM sense and antisense primers. Primer concentra-
tions were determined by preliminary experiments
that analyzed the optimal concentrations of each primer.
Each sample was run in triplicate in separate tubes to
permit quantification of the gene normalized to the 18s
rRNA. The PCR conditions were as follows: 35 cycles
of denaturation at 94.5 for 30 sec, annealing at 60℃
for 30 sec, and extension at 72 for 1 minute.℃ ℃
Initial heating at 95 for 9 minutes and final extension℃
at 72 for 7 minutes were performed for all PCRs.℃
After real-time PCR, the temperature was increased
from 60 to 95 at a rate of 2 /min to construct a℃ ℃
melting curve. A control without cDNA was run in
parallel with each assay. The cDNA content of each
specimen was determined using a comparative CT
method with 2- CT∆∆ . The results are given as relative
expression of ICAM-1 and fibronectin normalized to
the expression of the 18s housekeeping gene.
7. Western blot analysis
Renal cortical tissue and cultured cells harvested
from plates were lysed in sodium dodecyl sulfate
(SDS) sample buffer (2% sodium dodecyl sulfate, 10
mM Tris-HCl, pH 6.8, 10% [vol/vol] glycerol), treated
with Laemmli sample buffer, heated at 100 for 5℃
minutes, and electrophoresed in an 8% acrylamide
denaturing SDS-polyacrylamide gel. Proteins were
then transferred to a Hybond-ECL membrane using
a Hoeffer semidry blotting apparatus (Hoeffer Instru-
ments, San Francisco, CA, USA), and the membrane
was then incubated in blocking buffer A (1 PBS,×
0.1% Tween-20, and 8% nonfat milk) for 1 hour at
room temperature, followed by an overnight incubation
at 4 in a 1:1,000 dilution of polyclonal antibodies to℃
rat ICAM-1 (R&D systems, Minneapolis, MN, USA),
fibronectin (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA, USA), or -actin (Sigma, St. Louis, MO,β
USA). The membrane was then washed once for 15
minutes and twice for 5 minutes in 1 PBS with 0.1×
% Tween-20. Next, the membrane was incubated in
buffer A containing a 1:1,000 dilution of horseradish
peroxidase-linked donkey anti-goat IgG (Amersham
Life Science, Inc., Arlington Heights, IL, USA). The
washes were repeated, and the membrane was de-
veloped with a chemiluminescent agent (ECL; Amer-
sham Life Science, Inc.). The band densities were
measured using TINA image software (Raytest,
Straubenhardt, Germany).
8. Statistical analysis
All values are expressed as the mean standard±
error of the mean (SEM). Statistical analysis was per-
formed using the statistical package SPSS for Windows
Ver. 11.0 (SPSS, Inc., Chicago, IL, USA). Results were
analyzed using the Kruskal-Wallis non-parametric
test for multiple comparisons. Significant differences
by the Kruskal-Wallis test were further confirmed by
the Mann-Whitney U test. p values less than 0.05
were considered to be statistically significant.
RESULTS
1. Effect of colchicine on AII concentrations
AII levels in conditioned media were significantly
higher in HG-stimulated mesangial cells (7.21 1.12±
pg/ L) and NRK-52E cells (3.11 0.53 pg/ L) comμ ± μ -
pared to NG cells (4.38 0.64 pg/ L, 1.45 0.23 pg/ L,± μ ± μ
respectively) (N=5) (p<0.05). However, the increases
in AII concentrations in HG cells were not significantly
changed by colchicine (mesangial cells, 7.10 1.15 pg/±
L; NRK-52E cells, 3.21 0.45 pg/ L) (N=5). On theμ ± μ
other hand, mannitol had no effect on AII concentra-
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tions in conditioned culture media.
2. Effect of colchicine on 125I-AII binding
125I-AII-specific binding was significantly reduced
in HG-treated mesangial cells and NRK-52E cells
compared to NG cells, but colchicine had no significant
effect on 125I-AII-specific binding in cells exposed to
NG or HG medium (Fig. 1).
3. Effect of colchicine on high glucose- and
AII-induced ICAM-1 expression
ICAM-1 mRNA expression assessed by real-time
PCR was significantly induced in HG-stimulated me-
sangial cells (p<0.01) and NRK-52E cells (p<0.05).
AII also significantly increased ICAM-1 mRNA ex-
pression in cultured mesangial cells (p<0.01) and
NRK-52E cells (p<0.01) compared to NG cells. The
ICAM-1 mRNA/18s rRNA ratios were 2.1- and 2.0-
folds higher in HG-stimulated mesangial cells and
tubular epithelial cells, respectively, and 2.2- and
2.3-folds higher in AII-stimulated mesangial cells
and tubular epithelial cells, respectively. These in-
creases in ICAM-1 mRNA expression in HG- and
AII-stimulated cells were significantly abrogated by
the administration of colchicine or L-158,809 (Fig.
2). The protein expression of ICAM-1 showed a si-
Fig. 1.
125
I-AII-specific binding in mesangial cells (A)
and NRK-52E cells (B) cultured in 5.6 mM glu-
cose (NG), NG+10
-8
M colchicine (NG+Col), NG+
24.4 mM mannitol (NG+M), 30 mM glucose (HG),
or HG+10-8 M colchicine (HG+Col) (N=5). 125I-
AII-specific binding was significantly decreased
in HG-stimulated mesangial cells and tubular
epithelial cells compared to NG cells. However,
colchicine had no significant effect on
125
I-AII-
specific binding in cells exposed to NG or HG
medium. *p<0.05 vs. NG cells.
Fig. 2. ICAM-1 mRNA/18s rRNA ratios in mesangial
cells (A) and NRK-52E cells (B) cultured in 5.6
mM glucose (NG), NG+24.4 mM mannitol (NG+
M), 30 mM glucose (HG), or NG+10
-7
M AII (NG+
AII) with or without 10
-8
M colchicine (Col) and/
or 10-6 M L-158,809 (ARB) (N=6). The ICAM-
1 mRNA/18s rRNA ratios were 2.1- and 2.2-folds
higher in HG- and AII-stimulated mesangial cells,
respectively, and 2.0- and 2.3-folds higher in HG-
and AII-treated tubular epithelial cells, respec-
tively. These increases in ICAM-1 mRNA ex-
pression in HG- and AII-stimulated renal cells
were significantly abrogated by the administration
of Col or ARB. However, there was no additive
inhibitory effect of Col and ARB on the increase
in ICAM-1 mRNA expression in cells exposed
to HG or AII.
*
p<0.01 vs. NG cells,
†
p<0.05 vs.
HG- and AII-treated cells, ‡p<0.05 vs. NG cells.
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milar pattern to its mRNA expression (Fig. 3). On the
other hand, there was no additive or synergistic effect
of colchicine and L-158,809 on HG- and AII-induced
ICAM-1 expression.
4. Effect of colchicine on high glucose- and
AII-induced fibronectin expression
The fibronectin mRNA/18s rRNA ratios were signi-
ficantly increased in HG-stimulated mesangial cells
(p<0.01) and NRK-52E cells (p<0.05) relative to NG
cells by 115.5% and 82.4%, respectively. In addition,
there were significant increases in fibronectin mRNA
expression in AII-stimulated mesangial cells (p<0.01)
and tubular epithelial cells (p<0.01). These increases
in fibronectin mRNA expression in HG- and AII-
stimulated cells were significantly ameliorated with
colchicine or L-158,809 treatment (Fig. 4). The ex-
pression of fibronectin protein was also significantly
induced in HG- and AII-stimulated cells, and colchi-
cine and L-158,809 significantly attenuated these in-
creases in fibronectin protein expression (Fig. 5). On
the other hand, there was no additive or synergistic
effect of colchicine and L-158,809 on HG- and AII-
induced fibronectin expression
DISCUSSION
We previously found that colchicine prevented renal
injury in experimental diabetic nephropathy via inhi-
biting ICAM-1 and fibronectin expression6), but the
underlying mechanism how it abrogated increased
ICAM-1 and fibronectin expression under diabetic
conditions has not clarified yet. In this study, it is de-
monstrated for the first time that colchicine ameliorates
AII-induced ICAM-1 and fibronectin expression in
cultured renal cells without any significant influence
on binding of AII to its receptor, suggesting that the
Fig. 3. A representative Western blot of ICAM-1 in mesangial cells (MC) (A) and
NRK-52E cells (tubular epithelial cells, TEC) (B) cultured in 5.6 mM glucose
(NG), NG+24.4 mM mannitol (NG+M), 30 mM glucose (HG), or NG+10
-7
M
AII (NG+AII) with or without 10
-8
M colchicine (Col) and/or 10
-6
M L-
158,809 (ARB) (representative of four blots). ICAM-1 protein expression
was significantly increased in HG- and AII-stimulated cells compared to NG
cells, and these increases were significantly ameliorated by colchicine or ARB
treatment. However, there was no additive inhibitory effect of Col and ARB
on the increase in ICAM-1 protein expression in cells exposed to HG or AII.
-actin protein expression was comparable among the groups.β
*
p<0.05 vs. NG
cells, †p<0.05 vs. HG- and AII-treated cells, ‡p<0.01 vs. NG cells.
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beneficial effect of colchicine may be mediated by
inhibiting increased locally-produced AII under dia-
betic conditions.
Even though the diabetic milieu per se, hemodyna-
mic changes, and local growth factors such as AII are
considered mediators in the pathogenesis of diabetic
nephropathy19), the underlying pathways mediating
these processes are still under investigation. Among
these, numerous previous clinical and experimental
studies on diabetic nephropathy have demonstrated
that RAS blockades reduced proteinuria and the pro-
gression of renal lesions, which cannot be explained
merely by their antihypertensive effect20-22). These
findings suggest that RAS inhibition may have direct
effects on various renal cells. Indeed, mounting evi-
dence has shown that the local RAS exists in various
renal cells and is activated under diabetic conditions.
All RAS components were revealed to be present in
proximal tubular cells23), mesangial cells17, 24), and po-
docytes25), and the expression of angiotensinogen, the
substrate for AII, was increased in these cells under
diabetic conditions17, 23-25). In addition, high glucose
activated the local RAS leading to an increase in AII
levels23-25), known to induce ICAM-1, MCP- 1, and
fibronectin expression in mesangial cells26-28) and renal
tubular cells29-31). Taken together, activated local RAS
under diabetic conditions seems to play an important
role in the pathogenesis of diabetic nephropathy via
facilitating inflammation and extracellular matrix (ECM)
synthesis. In the present study, we also confirmed that
AII levels were significantly higher in high glucose-
conditioned media compared to NG media and that ARB
significantly inhibited increased ICAM-1 and fibronectin
expression in cultured mesangial cells and tubular epi-
thelial cells exposed to high glucose media, suggesting
that high glucose-induced AII may contribute to the
enhanced expression of ICAM-1 and fibronectin in
renal cells under diabetic conditions.
Colchicine is an alkaloid drug that has been used
for many decades in acute gouty arthritis. Colchicine
binds to tubulin molecules and inhibits their polymeri-
zation into microtubules, resulting in disruption of the
mitotic spindles8). Due to this basic property, colchicine
is mainly considered to be an anti-mitotic drug. How-
ever, accumulating evidence has shown its additional
effects on leukocytes and fibroblasts32-36). Colchicine
is known to alter leukocyte functions, such as chemo-
taxis, adhesion, and cytokine production35). In addition,
colchicine inhibits the release of fibronectin and col-
lagen to the extracellular space, reduces collagen-
Fig. 4. Fibronectin mRNA/18s rRNA ratios in mesangial
cells (A) and NRK-52E cells (B) cultured in 5.6
mM glucose (NG), NG+24.4 mM mannitol (NG+
M), 30 mM glucose (HG), or NG+10-7 M AII (NG+
AII) with or without 10
-8
M colchicine (Col) and/
or 10
-6
M L-158,809 (ARB) (N=6). The fibro-
nectin mRNA/18s rRNA ratios were significantly
increased in HG-stimulated mesangial cells and
tubular epithelial cells compared to NG cells by
115.5% and 82.4%, respectively. In addition, there
were significant increases in fibronectin mRNA
expression in AII-treated renal cells. These in-
creases in fibronectin mRNA expression in HG-
and AII-stimulated cells were significantly at-
tenuated by the administration of Col or ARB.
However, there was no additive inhibitory effect
of Col and ARB on the increase in fibronectin
mRNA expression in cells exposed to HG or AII.
*p<0.01 vs. NG cells, †p<0.05 vs. HG- and AII-
treated cells,
‡
p<0.05 vs. NG cells.
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processing enzyme, stimulates tissue collagenase acti-
vity, and inhibits the proliferation of fibroblasts33-35).
Based on these anti-inflammatory and anti-fibrotic
effects of colchicine, it has been used effectively to
treat various diseases such as familial Mediterranean
fever37, 38), primary biliary cirrhosis
39, 40), and Behcet s’
syndrome41).
The beneficial effects of colchicine have also been
demonstrated in several experimental kidney disease
models, including severe crescentic glomerulonephritis,
chronic cyclosporine nephrotoxicity, and diabetic ne-
phropathy via anti-inflammatory, anti-fibrotic, and
ant-apoptotic mechanisms6, 13, 42-44). In addition, col-
chicine was revealed to inhibit the increases in ICAM-
1 and fibronectin expression under diabetic conditions
both in vivo and in vitro6). In that study, however, the
underlying mechanism how colchicine abrogated the
increases in ICAM-1 and fibronectin expression under
diabetic conditions was not elucidated, leaving us with
another question: how does colchicine inhibit the up-
regulation of these genes expression under diabetic
conditions? Zhou et al15) demonstrated that AII-induced
nuclear factor- B in renal tubular cells was signifiκ -
cantly attenuated by coadministration of losartan, a
selective ARB, or colchicine, a selective cytoskeleton
microtubule inhibitor known to block receptor-mediated
endocytosis. Moreover, another recent study using
the same cell line showed that intracellular accumula-
tion of AII in response to extracellular AII, which was
mediated by AT1R, was significantly ameliorated by
not only losartan but also colchicine14). These findings
suggest extracellular AII may play a functional role
through internalization via AT1R-mediated endocy-
tosis and that colchicine may indirectly inhibit the
action of AII. Taken together, we proposed that the
inhibitory effect of colchicine on the expression of
these genes may be attributed to the suppressed action
of locally-produced AII under high glucose conditions
Fig. 5. A representative Western blot of fibronectin in mesangial cells (MC) (A) and
NRK-52E cells (tubular epithelial cells, TEC) (B) cultured in 5.6 mM glucose
(NG), NG+24.4 mM mannitol (NG+M), 30 mM glucose (HG), or NG+10
-7
M
AII (NG+AII) with or without 10-8 M colchicine (Col) and/or 10-6 M L-
158,809 (ARB) (representative of four blots). Fibronectin protein expression
was significantly increased in HG- and AII-stimulated cells compared to NG
cells, and these increases were significantly abrogated by colchicine or ARB
treatment. However, there was no additive inhibitory effect of Col and ARB
on the increase in fibronectin protein expression in cells exposed to HG or
AII. -actin protein expression was comparable among the groups.β *; p<0.05
vs. NG cells,
†
p<0.05 vs. HG- and AII-treated cells,
‡
p<0.01 vs. NG cells.
Eun Jin Kim, et al.: Effects of Colchicine and Angiotensin II on ICAM-1 and Fibronectin Expression
- 583-
in renal cells. This hypothesis is supported by our
findings that AII concentrations are increased in high
glucose-conditioned culture media and that colchicine
attenuates high glucose- and AII-induced ICAM-1
and fibronectin expression. Furthermore, the results
of this study showing that 125I-AII-specific binding
was not changed by colchicine, indicating no significant
direct effect of colchicine on the binding of AII to
AT1R, and that there was no additive inhibitory effect
of colchicine and ARB on ICAM-1 and fibronectin
expression infer that colchicine and ARB may partly
act on a common pathway under diabetic conditions.
In summary, colchicine abrogates increased ICAM-
1 and fibronectin expression in renal cells under dia-
betic conditions, partly mediated by inhibiting high glu-
cose-induced locally-produced AII. These findings
provide a new renoprotective mechanism of colchicine
in diabetic nephropathy in addition to its impact on
leukocyte functions.
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